Health Condition 1: null- The study is an observational study and will require Early Stage Renal Disease (ESRD) patients who are already on Hemo dialysis or Peritoneal dialysis.
Conditions
Interventions
None listed
Sponsors
Baxter India Private Limited
Baxter India Private Limited
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients should be between 18-65 years of age 2.Patients should have completed minimum of 3 months on one mode of dialysis 3. Patients who are on HD for at least 10 sessions a month (prevalent practice) 4. Patients undergoing CAPD with at least 3 exchanges per day (prevalent practice) 5. Patients on dextrose based solutions for CAPD 6. Patients shifted from another renal replacement therapy but have completed 3 months on new modality 7. Patient willing to give informed consent
Exclusion criteria
Exclusion criteria: 1. Patients who are on dialysis for less than 3 months 2. Patients on Automated Peritoneal Dialysis 3. Patients using Extraneal as exchange fluid for PD 4. Patients with Hepatitis B & C and HIV infection 5. Patients having Charlson Co-morbidity index 5 6. Patients with mental or neurological disorders, that might make their survey questionable 7. Patients unwilling to cooperate 8. Patients with expected life expectancy less than 1 year 9. Pregnancy and women of child bearing age who are planning for conception in next 12 months (duration of the study) 10. Patients under any reimbursement or health insurance scheme without proper supporting bills 11. Patient expected to be transferred to a non participating center within the period of study 12. Patients who previously have received kidney transplant or intend to receive kidney transplant in next 3 months 13. Patients with concomitant participation in any other interventional study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cost of ongoing HD versus CAPD therapy per year to patient & family (Direct & Indirect)Timepoint: Week 12, week 24, week 36 and week 48 | — |
Secondary
| Measure | Time frame |
|---|---|
| User satisfaction with HD and PD therapy Cost Utility of CAPD versus HD therapy in one yearTimepoint: Week 12, Week 24, Week 36 and Week 48 | — |
Countries
India
Contacts
Public ContactDr Rohit Roshan
Baxter (India) Private Limited
Outcome results
None listed